AMLX — Amylyx Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Amylyx Pharmaceuticals Q1 net loss widens more than expected on higher R&D costs
Brief: Amylyx Pharmaceuticals Q4 Operating Income USD -36.605 Million Versus. Ibes Estimate USD -40.4 Million
Amylyx Pharmaceuticals Q4 net loss beats estimates
U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, Humana
Amylyx rises after promising early-stage trial for ALS drug
Brief: Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114
Amylyx Pharma Q3 loss narrows
Brief: Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy
U.S. STOCKS ON THE MOVE-Waldencast, Danaher, Asset Entities
U.S. STOCKS ON THE MOVE-Nike, US chipmakers, Greenwich LifeSciences
Amylyx Pharma slips on $175 mln stock offering
Brief: Amylyx Pharmaceuticals Announces Pricing Of $175 Million Underwritten Public Offering Of Common Stock
Amylyx Pharma dips after stock offering launch
Brief: Amylyx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Victoria's Secret, Copper miners, Dell
Brief: Amylyx Pharmaceuticals Says FDA Granted Voluntary Request To Withdraw Approval Of Relyvrio